Literature DB >> 3968624

Propranolol therapy for portal hypertension in children.

S Ozsoylu, N Koçak, A Yüce.   

Abstract

Administration of propranolol to 13 children with portal hypertension reduced splenic pulp pressure by greater than 50 mm H2O (P less than 0.01) in approximately 2 weeks, when the pulse rate became three fourths the initial rate. The influence was found to be greater in compensated than in decompensated portal hypertension. This observation might be interpreted to mean that the effect of propranolol in the reduction of portal venous pressure results not only from decreased intestinal blood flow secondary to decreased cardiac output but also to the stimulation of sympathetic nervous system alpha-adrenoreceptors of the portal tract. Although arterial blood pressure changes were not significant, peripheral venous pressure was reduced significantly (P less than 0.01). We conclude that propranolol has considerable usefulness in treating portal hypertension in children.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3968624     DOI: 10.1016/s0022-3476(85)80316-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  15 in total

Review 1.  Current clinical management of hepatic problems in cystic fibrosis.

Authors:  M S Tanner
Journal:  J R Soc Med       Date:  1986       Impact factor: 5.344

Review 2.  The medical prevention of variceal bleeding.

Authors:  D Lebrec
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

Review 3.  Current management of primary sclerosing cholangitis in pediatric patients.

Authors:  Samar H Ibrahim; Keith D Lindor
Journal:  Paediatr Drugs       Date:  2011-04-01       Impact factor: 3.022

Review 4.  Screening and Prophylaxis for Varices in Children with Liver Disease.

Authors:  Molly A Bozic; Kanika Puri; Jean P Molleston
Journal:  Curr Gastroenterol Rep       Date:  2015-07

Review 5.  Primary prophylaxis of variceal hemorrhage in children with portal hypertension: a framework for future research.

Authors:  Simon C Ling; Thomas Walters; Patrick J McKiernan; Kathleen B Schwarz; Guadalupe Garcia-Tsao; Benjamin L Shneider
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-03       Impact factor: 2.839

Review 6.  Medical management of chronic liver diseases (CLD) in children (part II): focus on the complications of CLD, and CLD that require special considerations.

Authors:  Mortada H F El-Shabrawi; Naglaa M Kamal
Journal:  Paediatr Drugs       Date:  2011-12-01       Impact factor: 3.022

Review 7.  Interventions for preventing and managing advanced liver disease in cystic fibrosis.

Authors:  Senthil K Palaniappan; Nan Nitra Than; Aung Win Thein; Soe Moe; Indra van Mourik
Journal:  Cochrane Database Syst Rev       Date:  2017-08-29

Review 8.  Treatment of portal hypertension in children.

Authors:  J G Maksoud; M E Gonçalves
Journal:  World J Surg       Date:  1994 Mar-Apr       Impact factor: 3.352

9.  Proximal splenorenal shunts for extrahepatic portal venous obstruction in children.

Authors:  A S Prasad; S Gupta; V Kohli; G K Pande; P Sahni; S Nundy
Journal:  Ann Surg       Date:  1994-02       Impact factor: 12.969

10.  Treatment for hepatitis C virus-induced portal hypertension in leukemic children.

Authors:  Rasha El-Ashry; Hala Abdel Malek; Essam A Desoky Ghayaty; Ahmed A El-Gendy; Ahmad Darwish; Youssef Al-Tonbary
Journal:  Med Oncol       Date:  2013-04-04       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.